Actinogen is advancing a revolutionary oral therapeutic, Xanamem^®, through pivotal trials to transform treatment for Alzheimer’s disease and major depressive disorder. Our vision is to improve lives by targeting brain cortisol with precision and innovation.

ACW secures funding beyond XanaMIA AD trial final results

Actinogen secures funding beyond the XanaMIA Alzheimer’s disease trial topline final results in November following the recent positive interim analysis outcome. A share placement and share purchase plan have been announced to raise up to approximately $17.0 million.

ACW December 2025 quarterly activity report & Appendix 4C

Actinogen has released its quarterly activity report and Appendix 4C f or the three-month period ended 31 December 2025.

ACW positive XanaMIA AD trial Interim Analysis outcome

The XanaMIA pivotal Alzheimer’s disease (AD) trial’s independent Data Monitoring Committee (DMC) has recommended that the trial continue without amendment after its interim analysis. In doing so, the DMC determined that the unblinded safety and efficacy data it reviewed support continuing the trial to its completion later in the year

ACW secures $4.3m of non-dilutive R&D tax funding

Actinogen has secured a second tranche of non-dilutive funding from Endpoints Capital worth $4.3m under a funding facility secured against the company’s forecast FY26 Research and Development Tax Incentive rebate.

The funding is provided by Endpoints as part of the overall funding package of up to $13.8m as announced on 30 June 2025.

ACW at Sachs Neuroscience & JPM week in San Francisco

The ACW senior executive team are attending the Sachs Associates 9th Annual Neuroscience Innovation Forum and holding meetings associated with the 44th Annual JP Morgan Healthcare Conference (JPM Week) in San Francisco. 

The presentation attached to the announcement summarises recent advances in the Xanamem AD program and the multiple, independent clinical trials supporting the likelihood of success in the current XanaMIA pivotal trial. The trial is due to report the outcome of its interim analysis in late January 2026 and final topline results in November 2026.

Final, 246th participant randomized in XanaMIA AD trial – topline results Nov 2026

ACW has announced the enrolment and start of treatment for the final participant in the XanaMIA phase 2b/3 Alzheimer’s disease trial. This means that topline, final results will be available in November 2026. Interim results are expected at the end of January 2026.

ACW is holding a live webinar & Q&A session 18 December 2025 at 11am Sydney time. Click HERE to register and join the live event, or to watch a replay after the event.